Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study

NCT03471559 is registered in ClinicalTrials.gov with Central Institute of Mental Health, Mannheim as lead sponsor.

NCT NCT03471559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03471559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study
Lead sponsor
Central Institute of Mental Health, Mannheim
Phase
Phase 1
Overall status
Terminated
Start date
December 10, 2018
Completion date
August 29, 2019
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics, bioavailability